The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-19
DOI
10.1038/s41598-018-37259-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
- (2018) Malgorzata Banys-Paluchowski et al. BMC CANCER
- The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer
- (2018) Malgorzata Banys-Paluchowski et al. BREAST CANCER RESEARCH AND TREATMENT
- Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
- (2018) E.J. Blok et al. CANCER TREATMENT REVIEWS
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
- (2017) M.J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
- (2017) Ian Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors
- (2017) Concetta Di Mauro et al. Scientific Reports
- Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
- (2017) Malgorzata Banys-Paluchowski et al. Scientific Reports
- High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast
- (2016) Eun Young Kim et al. Journal of Breast Cancer
- Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer
- (2016) Kyung-A Hyun et al. Oncotarget
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) E. Senkus et al. ANNALS OF ONCOLOGY
- VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis
- (2015) Lucas Vieira dos Santos et al. BREAST CANCER RESEARCH AND TREATMENT
- Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase-Plasminogen-Activator System in Early Breast Cancer Patients
- (2015) Michal Mego et al. Breast Journal
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
- (2014) François-Clément Bidard et al. LANCET ONCOLOGY
- Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
- (2014) Omar Al-Janabi et al. Biomed Research International
- Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients
- (2014) Natalia Krawczyk et al. Biomed Research International
- Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer
- (2013) D.S. Lang et al. BREAST
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
- (2013) N. Harbeck et al. EUROPEAN JOURNAL OF CANCER
- AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
- (2013) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-initiated angiogenesis and the uPA/uPAR system
- (2013) Johannes M. Breuss et al. Cell Adhesion & Migration
- Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
- (2012) I Witzel et al. BRITISH JOURNAL OF CANCER
- Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance
- (2012) WEI ZHANG et al. ONCOLOGY REPORTS
- Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
- (2010) H Taubert et al. BRITISH JOURNAL OF CANCER
- High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer
- (2010) M İlie et al. BRITISH JOURNAL OF CANCER
- UPA and PAI-1 Analysis from Fixed Tissues – New Perspectives for a Known Set of Predictive Markers
- (2010) K. Malinowsky et al. CURRENT MEDICINAL CHEMISTRY
- Reversibility of Epithelial-Mesenchymal Transition (EMT) Induced in Breast Cancer Cells by Activation of Urokinase Receptor-dependent Cell Signaling
- (2009) Minji Jo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now